Biden Admin Pays Ellume $231M To Build COVID-19 US Test Plant

The government seems to be betting the company’s over-the-counter at-home antigen diagnostic test will be a game changer in stopping the spread of the coronavirus.

The Biden administration has given Ellume $213.8M to build a factory in the US to produce their at-home OTC COVID-19 test.
• Source: Shutterstock/ Ellume Health (Shutterstock)

The Biden administration is paying Ellume Health $231.8m to build a factory in the US to boost production of their rapid COVID-19 at-home diagnostic test. Until the factory is built, the US will receive half the tests manufactured by the company in Australia.

In a joint press release from the Department of Defense and the Department of Health and Human Services, the US government announced on 1 February it has given the Australian...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Business

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind

 
• By 

The brunt of the tariff exposure stems from Singapore and Costa Rica, which together account for an estimated 70% to 80% of the tariff-related cost burden. Less than 10% of the exposure is tied to China.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.